Enhancer of zeste homologue 2 expression in breast carcinoma smears in relationship with p53, Ki-67 and other prognostic parameters

Acta Cytologica

Volumn 55, Issue 2, 2011, Pages 180-186

  Athanassiadou, Anna Maria ^a   Tsipis, Angelos ^a   Patsouris, Efstratios ^a   Gonidi, Maria ^b   Nicolopoulou Stamati, Polyxeni ^a   Chelidonis, George ^a   Athanassiadou, Pauline ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b Hospital of Corfu   (Greece)

Author keywords

Breast carcinoma; EZH 2; Ki 67; p53

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; PROTEIN P53; TRANSCRIPTION FACTOR EZH2; DNA BINDING PROTEIN; EZH2 PROTEIN, HUMAN; TRANSCRIPTION FACTOR;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; BREAST CARCINOMA; CANCER CELL; CANCER GRADING; CANCER PATIENT; CANCER SIZE; CANCER SURVIVAL; CELL NUCLEUS; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; IMMUNOREACTIVITY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; BREAST TUMOR; CHI SQUARE DISTRIBUTION; CYTOLOGY; METABOLISM; MIDDLE AGED; PAGET NIPPLE DISEASE; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; STATISTICAL MODEL; SURVIVAL;

AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CELL NUCLEUS; CHI-SQUARE DISTRIBUTION; CYTOLOGICAL TECHNIQUES; DNA-BINDING PROTEINS; FEMALE; HUMANS; KI-67 ANTIGEN; LOGISTIC MODELS; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; SURVIVAL ANALYSIS; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 79955652051     PISSN: 00015547     EISSN: 19382650     Source Type: Journal    
DOI: 10.1159/000320790     Document Type: Article

References (38)

1. Daidone MG, Povradiso A, Gion M, Harbeck N, Sweep F, Schmitt M: Biomolecular features of clinical relevance in breast cancer. Eur J Nucl Med Mol Imaging 2004; 31(suppl 1):S13-S14.
2. Mitra AP, Lin H, Cote RJ, Datar RH: Biomarker profiling for cancer diagnosis, prognosis and therapeutic management. Natl Med J India 2005; 18: 304-312.
3. Krajewski S, Krajewska M, Turner BC, Pratt C, Howard B, Zapata JM, Frenkel V, Robertson S, Ionov Y, Yamamoto H, Povrucho M, Takayama S, Reed JC: Prognostic significance of apoptosis regulators in breast cancer. Endocr Relat Cancer 1999; 6: 29-40.
4. Madjd Z, Mehrjerdi AZ, Sharifi AM, Molanaei S, Shahzadi SZ, Asadi-Lari M: CD44+ cancer cells express higher levels of the antiapoptotic protein Bcl-2 in breast tumors. Cancer Immun 2009; 9: 4.
5. Tan PH, Bay BH, Yip G, Selvovrajan S, Tan P, Wu J, Lee CH, Li KB: Immunohistochemical detection of Ki67 in breast cancer correlates with transcriptional regulation of genes related to apoptosis and cell death. Mod Pathol 2005; 18: 374-381.
6. Daidone MG, Luisi A, Veneroni S, Benini E, Silvestrini R: Clinical studies of Bcl 2 and treatment benefit in breast cancer patients. Endocr Relat Cancer 1999; 6: 61-68.
7. Dalquen P, Baschiera B, Chaffard R, Dietrich H, Feichter GE, Kremer K, Torhosst J: MIB- 1(Ki-67) immunostaining of breast cancer cells in cytologic smears. Acta Cytol 1997; 41: 229-237.
8. Itaya M, Yoshimoto J, Kojima K, Kawasaki S: Immunohistochemistry of p53, Bcl-2 and Ki-67 as predictors of chemosensitivity. Methods Mol Med 2005; 110: 213-227.
9. Sherr CJ, McCormick F: The RB and p53 pathways in cancer. Cancer Cell 2002; 2: 103-112.
10. Zeidler M, Kleer C: The Polycomb group protein Enhancer of Zeste 2: its links to DNA repair and breast cancer. J Mol Histol 2006; 37: 219-223.
11. Tonini T, D'andrilli G, Fucito A, Gaspah L, Bagella L: Importance of EZH 2 polycomp protein in tumorigenesis process interfering with the pathway of growth suppressive key elements. J Cell Physiol 2008; 214: 295-300.
12. Ding L, Kleer C: Enhancer of Zeste 2 as a marker of preneoplastic progression in the breast. Cancer Res 2006; 66: 9352-9355.
13. Wei Y, Xia W, Zhang Z, Liu J, Wanh H, Adsay N, Abbarracin C, Yu D, Abbruzzese J, Mills G, Bast R, Hortobagyu G, Hung MC: Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor outcome in breast, ovarian, and pancreatic cancers. Mol Carcinog 2008; 47: 701-706.
14. Simon JA, Lange CA: Roles of the EZH2 histone methyltransferase in cancer epigenetics. Mutat Res 2008; 647: 21-29.
15. Koss LG, Melamed R (eds): Koss' Diagnostic Cytology and Its Histopathologic Bases, ed 5. Philadelphia, Lippincott Williams & Wilkins, 2005, vol 2, pp 1592-1593, 1615- 1616.
16. Tavassoli F, Devilee P (eds): World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of the Breast and Female Genital Organs. Lyon, IARC Press, 2003, p 10.
17. Page DL, Anderson TJ: Diagnostic Histopathology of the Breast. Edinburgh, Churchill Livingstone, 1987, pp 303-307.
18. Cytology Subgroup of the National Coordinating Committee for Breast Cancer Screening Pathology: Guidelines for cytology procedures and reporting on fine needle aspirates of the breast. Cytopathology 1994; 5: 316-334.
19. Bast RC, Raudin P, Hayes DF, et al: 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001; 19: 1865-1878.
20. Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN: Overview of resistance to systemic therapy in patients with breast cancer. Adv Exp Med Biol 2007; 608: 1-22.
21. Tsakonas G, Kosmas C: Integration of novel targeted therapies into the systemic treatment of breast cancer - a review. J BUON 2007; 12: 319-327.
22. Cotter TG: Apoptosis and cancer: the genesis of a research field. Nat Rev Cancer 2009; 9: 501-507.
23. Shen Y, White E: p53 dependent apoptosis pathways. Adv Cancer Res 2001; 82: 55-84.
24. Wiesner F, Magener A, Fasching P, Wesse J, Bani M, Rauh C, Jud S, Schraceder M, Loehberg C, Beckmann M, Hartmann A, Lux M: Ki-67 as a prognostic molecular marker in routine clinical use in breast cancer patients. Breast 2009; 18: 135-141.
25. von Minckwitz G, Sinn HP, Raab G, Loibl S, Blohmer JU, Eidtmann H, Hilfrich J, Merkle E, Jackisch C, Costa S, Caputo A, Kaufmann M, German Breast Group: Clinical response after two cycles compared to HER2, Ki-67, p53, and bcl-2 in independently predicting a pathological complete response after preoperative chemotherapy in patients with operable carcinoma of the breast. Breast Cancer Res 2008; 10:R30.
26. Jacquemier J, Charafe-Jauffret E, Monville F, Esterni B, Extra J, Houvenaeghel G, Xerri L, Bertucci F, Birnbaum D: Association of GATA3, p53, Ki67 status and vascular peritumoral invasion are strongly prognostic in luminal breast cancer. Breast Cancer Res 2009; 11:R23.
27. Collett K, Eide G, Ames H, Stefansson I, Eide J, Brocaten A, Aas T, Otte A, Akslen L: Expression of Enhancer of Zeste homologue 2 is significantly associated with increased tumor cell proliferation and is a marker of aggressive breast cancer. Clin Cancer Res 2006; 12: 1168-1175.
28. Mattiou E, Vogiatzi P, Sun A, Abbadessa G, Angeloni G, D'ugo D, Trani D, Gaughan J, Vecchio F, Cevenini G, Persiani R, Giordano A, Claudio P: Immunohistochemical analysis of pRb2/p130, VEGF, EZH 2, p53, p16 INK4A , p27 KIP1 , p21 WAF1 , Ki-67 expression patterns in gastric cancer. J Cell Physiol 2007; 210: 183-191.
29. Takeshita F, Minakuchi Y, Naghahara S, Honma K, Sasaki H, Hirai K, Teratani T, Namatame N, Yamamoto Y, Hanai K, Kato T, Sano A, Ochiya T: Efficient delivery of small interfering RNA to bone-metastatic tumors by using atelocollagen in vivo. Proc Natl Acad Sci USA 2005; 102: 12177-12182.
30. Machmann I, Haluorsen O, Collett K, Stefansson I, Straume O, Haukaas S, Salvesen H, Otte A, Akslen L: EZH 2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate and breast. J Clin Oncol 2006; 24: 268-273.
31. Kleer C, Cao Q, Varambally S, Shen R, Ota I, Tomlins S, Ghosh D, Sewalt R, Otte A, Hayes D, Sabel M, Livant A, Weiss S, Rubin M, Chinnaiyan A: EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci USA 2003; 100: 11606-11611.
32. Raaphorst FM, Meijer CJ, Fieret E, et al: Poorly differentiated breast carcinoma is associated with increased expression of the human polycomb group EZH 2 gene. Neoplasia 2003; 5: 481-488.
33. van't Veer LJ, Dai H, van de Vijver M, He Y, Hart A, Mao M, Peterse H, van der Kooy K, Marton M, Witteveen A, et al: Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002; 415: 530-536.
34. van der Vlag J, Otte A: Transcriptional repression mediated by the human polycombgroup protein EED involves histone deacetylation. Nat Genet 1999; 23: 474-478.
35. Beier R, Burgin A, Kiermaier A, et al: Induction of cyclin E-cdK2 kinase activity, E2Fdependent transcription and cell growth by Myc are genetically separable events. EMBO J 2000; 19: 5813-5823.
36. Bracken AP, Pasini D, Capra M, et al: EZH 2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer. EMBO J 2003; 22: 5323-5335.
37. Tang X, Milyavsky M, Shats I, et al: Activated p53 suppresses the histone methyltransferase EZH 2 gene. Oncogene 2004; 23: 5759-5769.
38. Norberg T, Klaar S, Kourf G, et al: Increased p53 mutation frequency during tumor progression- results from a breast cancer cohort. Cancer Res 2001; 61: 8317-8321.